Bristol Myers Squibb Highlights Hematology Advances at ASH 2026
Princeton, New Jersey, United States, November 19, 2026 Bristol Myers Squibb (BMS) has announced an extensive programme of new...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 Clinical Trial Phase 3 trial Precision Medicine Precision Oncology rare disease solid tumors targeted therapy
Princeton, New Jersey, United States, November 19, 2026 Bristol Myers Squibb (BMS) has announced an extensive programme of new...
